Graviton Clears GV101 Phase II Entry in Friedreich’s Ataxia
Graviton BioScience said the FDA cleared an investigational new drug application for a capsule formulation of GV101, an oral selective ROCK2 inhibitor, enabling a planned randomized Phase II study in Friedreich’s ataxia. The study…
